These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 8126502)

  • 21. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
    Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Illi A; Suominen K; Keränen T
    Eur J Clin Pharmacol; 1993; 45(5):419-23. PubMed ID: 8112370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
    Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COMT inhibition: a new treatment strategy for Parkinson's disease.
    Kurth MC; Adler CH
    Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
    Nutt JG; Woodward WR; Beckner RM; Stone CK; Berggren K; Carter JH; Gancher ST; Hammerstad JP; Gordin A
    Neurology; 1994 May; 44(5):913-9. PubMed ID: 8190296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
    Stocchi F; Barbato L; Nordera G; Bolner A; Caraceni T
    J Neural Transm (Vienna); 2004 Feb; 111(2):173-80. PubMed ID: 14767720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
    Ruottinen HM; Rinne UK
    J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):36-40. PubMed ID: 8558148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
    Trocóniz IF; Naukkarinen TH; Ruottinen HM; Rinne UK; Gordin A; Karlsson MO
    Clin Pharmacol Ther; 1998 Jul; 64(1):106-16. PubMed ID: 9695725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Entacapone: is it useful as complimentary treatment with levodopa?].
    Burguera JA; Grandas F; Horga de la Parte JF; Luquin R; Martí F; Matías-Guiu J; Obeso JA; Kulisevsky J
    Rev Neurol; 1999 Apr 16-30; 28(8):817-34. PubMed ID: 10363328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
    Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
    Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.